Back to Products
Semaglutide
LOT: PEP-24-38353-D

Semaglutide

Semaglutide is a long-acting GLP-1 (glucagon-like peptide-1) receptor agonist designed with structural modifications including a C18 fatty acid moiety for albumin binding and multiple amino acid substitutions that extend its half-life to approximately 7 days. It enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces central hunger signaling through hypothalamic GLP-1 receptor engagement. Extensive clinical research has established its efficacy in type 2 diabetes management and obesity treatment, with body weight reductions of approximately 15–17% observed in long-term studies. It represents the foundational reference standard against which next-generation incretin compounds including tirzepatide and retatrutide are compared in metabolic research.

Research Benefits

  • Modulates appetite and satiety through long-acting GLP-1 receptor agonism, reducing central hunger signaling and caloric intake in research models
  • Enhances glucose-dependent insulin secretion and slows gastric emptying, supporting glycemic regulation in type 2 diabetes and metabolic research
  • Supports significant body weight reduction (approximately 15–17%) and body composition improvement in long-term obesity research studies

Size

Quantity

Total Price$132.68
Semaglutide is a long-acting GLP-1 receptor agonist consisting of a modified 31-amino acid peptide sequence derived from native GLP-1(7–37). It was developed by Novo Nordisk with structural modifications that extend its plasma half-life to approximately 7 days, enabling weekly subcutaneous dosing. Since its development and regulatory approval, semaglutide has been studied extensively in controlled clinical settings for its potential influence on appetite signaling, glucose metabolism, cardiovascular risk reduction, and long-term weight management.